Prodrug/drug sensitivity gene therapy: Current status

Current Oncology Reports

Volumn 2, Issue 1, 2000, Pages 17-22

  Smythe, W Roy ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Bystander Effect; Ganciclovir; Gene Therapy; Malignant Pleural Mesothelioma; Thymidine Kinase

Indexed keywords

PRODRUG;

CLINICAL TRIAL; GENE THERAPY; GENETICS; HUMAN; METHODOLOGY; MULTIMODALITY CANCER THERAPY; NEOPLASM; REVIEW;

CLINICAL TRIALS; COMBINED MODALITY THERAPY; GENE THERAPY; HUMANS; NEOPLASMS; PRODRUGS; RESEARCH DESIGN;

EID: 0033732739     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-000-0006-z     Document Type: Article

References (41)

1. Culver KW, Ishii H, Blaese RM, et al.: In vivo gene transfer with retroviral vector producer cells for the treatment of experimental brain tumors. Science 1992, 256:1550–1552. DOI: 10.1126/science.1317968
2. Smythe WR, Hwang HC, Amin KM, et al.: Use of recombinant adenovirus to transfer the herpes simplex thymidine kinase gene (HSVtk) to thoracic neoplasms: an effective in vitro drug sensitization system. Cancer Res 1994, 54:2055–2059.
3. Smythe WR, Hwang HC, Elshami AA, et al.: Treatment of experimental human mesothelioma using adenovirus transfer of the herpes simplex thymidine kinase gene. Ann Surg 1995, 222:78–86. DOI: 10.1097/00000658-199507000-00013
4. Huber BE, Austin EA, Richards CA, et al.: Metabolism of 5-fluorocytidine to 5-fluorouracic in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effect when only a small percentage of tumor cells express cytosine deaminase. Proc Natl Acad Sci U S A 1994, 91:8392–8306.
5. Chen L, Waxman DJ, Chen D, Kufe DC: Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene. Cancer Res 1996, 56:1331–1340.
6. Tamiya T, Ono Y, Wei MX, et al.: Escherchia coli gpt gene sensitizes rat glioma cells to killing by 6-thioxanthine of 6-thioguaninie. Cancer Gene Ther 1996, 3:155–162.
7. Sorscher EJ, Peng S, Bebok Z, et al.: Tumor cell bystander killing in colonic carcinoma utilizing the Escherichia coli DeoD gene to generate toxic purines. Gene Therapy 1994, 1:233–238.
8. Friedlos F, Court S, Ford M, et al.: Gene-directed enzyme prodrug therapy: quantitative bystander cytotoxicity and DNA damage induced by CB1954 in cells expressing bacterial nitroreductase. Gene Ther 1998, 5:105–112. DOI: 10.1038/sj.gt.3300569
9. Marais R, Spooner RA, Light Y, et al.: Gene-directed enzyme prodrug therapy with a mustard prodrug/carboxypeptidase G2 combination. Cancer Res 1996, 56:4735–4742.
10. Elshami AA, Saavedra A, Zhang H, et al.: Gap junctions play a role in the ‘bystander effect’ of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. Gene Ther 1996, 3:85–92.
11. Mesnil M, Piccoli C, Tiraby G, et al.: Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc Natl Acad Sci U S A 1996, 93:1831–1835. DOI: 10.1073/pnas.93.5.1831
12. Vile R, Miller N, Chernayovsky Y, Hart I: A comparison of the properties of different retroviral vectors containing the tyrosinase promoter to achieve transcriptionally targeted expression of the HSVtk or IL-2 genes. Gene Ther 1994, 1:307–316.
13. Hamel W, Magnelli L, Chiarugi VP, Israel MA: Herpes simplex thymidine kinase/ganciclovir-mediated apoptotic death of bystander cells. Cancer Res 1996, 56:2697–2702.
14. Ishii-Morita H, Agrabaria R, Mullen CA, et al.: Mechanism of ‘bystander effect’ killing in the herpes simplex thymidine kinase gene therapy model of cancer treatment. Gene Ther 1997, 4:244–251. DOI: 10.1038/sj.gt.3300379
15. Vile RG, Nelson JA, Castleden S, et al.: Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res 1994, 54:6228–6234.
16. Gagandeep S, Brew R, Green B, et al.: Prodrug-activated gene therapy: Involvement of an immunological component in the "bystander effect". Cancer Gene Ther 1995, 3:83–88.
17. Smith JG, Raper SE, Wheeldon EB, et al.:.Intracranial administration of adenovirus expressing HSV-TK in combination with ganciclovir produces a dose-dependent, self-limiting inflammatory response. Human Gene Ther 1997, 8:943–954. Report from the first study to demonstrate that intracranial administration of adenoviral-mediated prodrug gene therapy was likely to be relatively nontoxic to human patients. Both gross and microscopic pathologic findings in nonhuman primates are also described.
18. Yamamoto S, Suzuki S, Hoshino A, et al.: Herpes simplex thymidine kinase/ganciclovir-mediated killing of tumor cells induces tumor-specific cytotoxic T cells in mice. Cancer Gene Ther 1997, 2:91–96.
19. Ramesh R, Munshi A, Abboud CN, et al.: Expression of costimulatory molecules: B7 and ICAM up-regulation after treatment with a suicide gene. Cancer Gene Ther 1996, 3:373–384.
20. Ramesh R, Marrogi AJ, Munshi A, et al.: In vivo analysis of the ‘bystander effect’: a cytokine cascade. Exper Hematol 1996, 24:829–838.
21. Niculescu-Duvaz I, Spooner R, Marais R, Springer CJ: Gene-directed enzyme prodrug therapy. Bioconjugate Chem 1998, 9:4–22. DOI: 10.1021/bc970116t
22. Wallace H, Clarke AR, Harrison ML, et al.: Ganciclovir-induced ablation of non-proliferating thyrocytes expressing herpes virus thymidine kinase occurs by p53-independent apoptosis. Oncogene 1996, 13:55–61.
23. Chen HS, Shine HD, Goodman RG, et al.: Gene therapy for brain tumors: Regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc Natl Acad Sci U S A 1994, 91:3054–3057. DOI: 10.1073/pnas.91.8.3054
24. Izquierdo M, Cortes M, de Felipe P, et al.: Long-term survival after malignant brain tumor regression by retroviral gene therapy. Gene Ther 1995, 2:66–69.
25. Rosolen A, Frascella E, di Francesco, et al.: In vitro and in vivo antitumo effects of retrovirus-mediated herpes simplex thymidine kinase gene-transfer in human medulloblastoma. Gene Ther 1998, 5:113–120. DOI: 10.1038/sj.gt.3300559
26. Goodman JC, Trask TW, Chen S-H, et al.: Adenoviral-mediated thymidine kinase gene transfer into the primate brain followed by systemic ganciclovir: pathologic, radiologic and molecular studies. Human Gene Ther 1996; 8:1241–1250.
27. Link CJ, Moorman D, Seregina T, et al.: A Phase I trial of in vivo gene therapy with the herpes simplex thymidine kinase gene/ganciclovir system for the treatment of refractory or recurrent ovarian cancer. Human Gene Ther 1996, 7:1161–1179.
28. Rosenfeld ME, Wang M, Siegal GP, et al.: Adenoviral-mediated delivery of herpes simplex thymidine kinase results in tumor reduction and prolonged survival in a SCID mouse model of human ovarian carcinoma. J Mol Med 1996, 74:455–462. DOI: 10.1007/s001090050047
29. Kucharczuk JC, Raper S, Alshami, et al.: Safety of intrapleurally administered recombinant adenovirus carrying herpes simplex thymidine kinase DNA followed by ganciclovir therapy in nonhuman primates. Human Gene Ther 1996, 7:2225–2233.
30. Smythe WR, Hwang HC, Amin K, et al.: Significant survival benefit following adenovirus-mediated gene therapy for expeimental malignant human mesothelioma. Surg Forum 1994, 45:499–502.
31. Ohwada A, Hirschowitz EA, Crystal RG: Regional delivery of an adenovirus vector containing the Escheridia Coli cytosine deaminase gene to provide local activation of 5-fluorocytosine to suppress the growth of colon carcinoma metastatic to the liver. Human Gene Ther 1996, 7:1567–1576.
32. Topf N, Worgall S, Hackett NR, Crystal RG: Regional "prodrug" gene therapy: intravenous administration of an adenoviral vector expressing the E. coli cytosine deaminase gene and systemic administration of 5-fluorocytosine suppresses growth of hepatic metastasis of colon carcinoma. Gene Ther 1998, 5:507–513. This animal model paper demonstrates the potential efficacy of the only prodrug gene therapy pardigm other than HSVtk now at the clinical trial stage. This group is currently applying the phase I use of this adenoviral-mediated cytosine deaminase/5-FC system in patients with metastatic colonic carcinoma to the liver. DOI: 10.1038/sj.gt.3300611
33. Ram Z, Culver KW, Oshiro EM, et al.: Therapy of malignant brain tumors by intratumoral implantation of retroviralvector producing cells. Nature Med 1997, 3:1354–1357. First human clinical report from the group that initiated the modern interest in prodrug gene therapy with impressive in vivo results in rodent models of glioblastoma earlier in the 1990’s [1]. Although gene transfer utilizing the retroviral packaging system is documented, the clinical effect was thought to be minimal. DOI: 10.1038/nm1297-1354
34. Izquierdo M, Martin V, de FelipeP, et al.: Human malignant brain tumor response to herpes simplex thymidine kinase (HSVtk)/ganciclovir gene therapy. Gene Ther 1996, 3:491–495.
35. Izquierdo M, Cortes ML, Martin V, et al.: Gene therapy in brain tumors: implications of the size of glioblastoma on its curability. Acta Neurochirgica 1997, S68:111–117.
36. Treat J, Sterman DH, Litzky LA, et al.: Adenovirus-mediated herpes simplex thymidine kinase gene delivery in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Human Gene Ther 1998, 9:1083–1092. This phase I clinical trial report demonstrates that adenoviral-mediated prodrug gene therapy in the pleural space is well tolerated, with minimal toxicity, and that gene transfer is possible at higher-density doses of vector. Although mesothelioma is an uncommon tumor, lessons learned from treatment of these patients may eventually be applicable to treatment of other human body cavity malignancies.
37. Herman JR, Adler HL, Aguilar-Cordova E, et al.: In situ gene therapy for edinocarcinoma of the prostate: a phase I clinical trial. Hum Gene Ther 1999, 10:1239–1249. DOI: 10.1089/10430349950018229
38. Zerrouqi A, Rixe O, Ghoumari AM, et al.: Liposomal delivery of the herpes simplex thymidine kinase gene in glioma: improvement of cell sensitization to ganciclovir. Cancer Gene Ther 1996, 3:385–392.
39. Uckert W, Kammertons T, Haack K, et al.: Double suicide gene (cytosine deaminase and herpes simplex virus thymidine kinase) but not single gene transfer allows reliable elimination of tumor cells in vivo. Human Gene Ther 1998, 9:855–865. DOI: 10.1089/10430349850019454
40. Aghi M, Kramm CM, Chou TC, et al.: Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/cytosine deaminase therapies. J Natl Cancer Inst 1998, 90:379–380. DOI: 10.1093/jnci/90.5.370
41. Hanna NN, Maurceri HJ, Wayne JD, et al.: Virally-directed cytosine deaminase/5 fluorocytosine gene therapy enhances radiation response in human cancer xenografts. Cancer Res 1997, 57:4205–4209.